Citadel Advisors
GMAB icon

Citadel Advisors’s Genmab GMAB Stock Holding History

Citadel Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.63M Buy
172,500
+145,600
+541% +$4.36M ﹤0.01% 4468
2025
Q4 		$829K Sell
26,900
-3,100
-10% -$96.6K ﹤0.01% 7833
2025
Q3 		$920K Buy
30,000
+11,700
+64% +$285K ﹤0.01% 7710
2025
Q2 		$378K Sell
18,300
-29,900
-62% -$614K ﹤0.01% 9280
2025
Q1 		$944K Buy
48,200
+32,500
+207% +$682K ﹤0.01% 7083
2024
Q4 		$328K Buy
15,700
+5,500
+54% +$121K ﹤0.01% 9474
2024
Q3 		$249K Buy
10,200
+3,400
+50% +$90.9K ﹤0.01% 9687
2024
Q2 		$171K Sell
6,800
-6,600
-49% -$187K ﹤0.01% 10156
2024
Q1 		$401K Buy
13,400
+1,700
+15% +$49.9K ﹤0.01% 8859
2023
Q4 		$373K Buy
11,700
+1,100
+10% +$34.5K ﹤0.01% 8706
2023
Q3 		$374K Buy
10,600
+6,000
+130% +$229K ﹤0.01% 8693
2023
Q2 		$175K Sell
4,600
-29,700
-87% -$1.18M ﹤0.01% 10091
2023
Q1 		$1.3M Buy
34,300
+31,300
+1,043% +$1.2M ﹤0.01% 6245
2022
Q4 		$127K Sell
3,000
-170,100
-98% -$7.01M ﹤0.01% 10857
2022
Q3 		$5.56M Buy
173,100
+91,600
+112% +$3.22M ﹤0.01% 3696
2022
Q2 		$2.65M Buy
81,500
+58,100
+248% +$1.88M ﹤0.01% 4992
2022
Q1 		$847K Buy
23,400
+16,800
+255% +$577K ﹤0.01% 8089
2021
Q4 		$261K Buy
6,600
+800
+14% +$33.4K ﹤0.01% 11241
2021
Q3 		$253K Sell
5,800
-5,000
-46% -$224K ﹤0.01% 11449
2021
Q2 		$441K Sell
10,800
-53,100
-83% -$2.05M ﹤0.01% 10333
2021
Q1 		$2.1M Buy
63,900
+40,600
+174% +$1.53M ﹤0.01% 6271
2020
Q4 		$947K Buy
23,300
+1,300
+6% +$48.6K ﹤0.01% 6906
2020
Q3 		$805K Buy
22,000
+3,900
+22% +$141K ﹤0.01% 6410
2020
Q2 		$613K Buy
+18,100
New +$493K ﹤0.01% 6706

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citadel Advisors's GMAB Position: Q1 2026 in Review

Citadel Advisors sold out of Genmab (GMAB) in Q1 2026, closing a stake of 19,102 shares — an estimated $572K sold.

Citadel Advisors first reported a position in GMAB in Q3 2019 and held it in 24 quarters. The position peaked at $86.7M in Q1 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Citadel Advisors reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 19,102 Genmab shares in Q1 2026, an estimated $572K.
  • Citadel Advisors first reported a position in Genmab in Q3 2019 and held it in 24 quarters.
  • Citadel Advisors's Genmab position peaked at $86.7M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.